Changlei Bao

Dr. Changlei Bao

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Circulation
Verified
Journal Article
Closed access
HTHaiyang Tang
Haiyang Tang
AGAkash Gupta
Akash Gupta
SMSeth A. Morrisroe
Seth A. Morrisroe
CBChanglei Bao
Changlei Bao
TSTae-Hwi Schwantes-An
Tae-Hwi Schwantes-An
ADAnkit A. Desai
Ankit A. Desai
BACKGROUND: The ubiquitin-proteasome system regulates protein degradation and the development of pulmonary arterial hypertension (PAH), but knowledge about the role of deubiquitinating enzymes in this process is limited. UCHL1 (ubiquitin carboxyl-terminal hydrolase 1), a deubiquitinase, has been shown to reduce AKT1 (AKT serine/threonine kinase 1) degradation, resulting in higher levels. Given that AKT1 is pathological in pulmonary hypertension, we hypothesized that UCHL1 deficiency attenuates PAH development by means of reductions in AKT1. METHODS: Tissues from animal pulmonary hypertension models as well as human pulmonary artery endothelial cells from patients with PAH exhibited increased vascular UCHL1 staining and protein expression. Exposure to LDN57444, a UCHL1-specific inhibitor, reduced human pulmonary artery endothelial cell and smooth muscle cell proliferation. Across 3 preclinical PAH models, LDN57444-exposed animals, Uchl1 knockout rats ( Uchl1 −/− ), and conditional Uchl1 knockout mice ( Tie2Cre-Uchl1 fl/fl ) demonstrated reduced right ventricular hypertrophy, right ventricular systolic pressures, and obliterative vascular remodeling. Lungs and pulmonary artery endothelial cells isolated from Uchl1 −/− animals exhibited reduced total and activated Akt with increased ubiquitinated Akt levels. UCHL1-silenced human pulmonary artery endothelial cells displayed reduced lysine(K)63-linked and increased K48-linked AKT1 levels. RESULTS: Supporting experimental data, we found that rs9321, a variant in a GC-enriched region of the UCHL1 gene, is associated with reduced methylation (n=5133), increased UCHL1 gene expression in lungs (n=815), and reduced cardiac index in patients (n=796). In addition, Gadd45α (an established demethylating gene) knockout mice ( Gadd45α −/− ) exhibited reduced lung vascular UCHL1 and AKT1 expression along with attenuated hypoxic pulmonary hypertension. CONCLUSIONS: Our findings suggest that UCHL1 deficiency results in PAH attenuation by means of reduced AKT1, highlighting a novel therapeutic pathway in PAH.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
CBChanglei Bao
Changlei Bao
QHQian He
Qian He
HWHui Wang
Hui Wang
YSYanan Sun
Yanan Sun
YXYahang Xu
Yahang Xu
HYHan Ying
Han Ying
Background. Pulmonary arterial hypertension (PAH) is a complex pulmonary vasculature disease characterized by progressive obliteration of small pulmonary arteries and persistent increase in pulmonary vascular resistance, resulting in right heart failure and death if left untreated. Artemisinin (ARS) and its derivatives, which are common antimalarial drugs, have been found to possess a broad range of biological effects. Here, we sought to determine the therapeutic benefit and mechanism of ARS and its derivatives treatment in experimental pulmonary hypertension (PH) models. Methods. Isolated perfused/ventilated lung and isometric tension measurements in arteries were performed to test pulmonary vasoconstriction and relaxation. Monocrotaline (MCT) and hypoxia+Su5416 (SuHx) were administered to rats to induce severe PH. Evaluation methods of ARS treatment and its derivatives in animal models include echocardiography, hemodynamics measurement, and histological staining. In vitro, the effect of these drugs on proliferation, viability, and hypoxia‐inducible factor 1α (HIF1α) was examined in human pulmonary arterial smooth muscle cells (hPASMCs). Results. ARS treatment attenuated pulmonary vasoconstriction induced by high K+ solution or alveolar hypoxia, decreased pulmonary artery (PA) basal vascular tension, improved acetylcholine‐ (ACh‐) induced endothelial‐dependent relaxation, increased endothelial nitric oxide (NO) synthase (eNOS) activity and NO levels, and decreased levels of NAD(P)H oxidase subunits (NOX2 and NOX4) expression, NAD(P)H oxidase activity, and reactive oxygen species (ROS) levels of pulmonary arteries (PAs) in MCT‐PH rats. NOS inhibitor, L‐NAME, abrogated the effects of ARS on PA constriction and relaxation. Furthermore, chronic application of both ARS and its derivative dihydroartemisinin (DHA) attenuated right ventricular systolic pressure (RVSP), Fulton index (right ventricular hypertrophy), and vascular remodeling of PAs in the two rat PH models. In addition, DHA inhibited proliferation and migration of hypoxia‐induced PASMCs. Conclusions. In conclusion, these results indicate that treatment with ARS or DHA can inhibit PA vasoconstriction, PASMC proliferation and migration, and vascular remodeling, as well as improve PA endothelium‐dependent relaxation, and eventually attenuate the development and progression of PH. These effects might be achieved by decreasing NAD(P)H oxidase generated ROS production and increasing eNOS activation to release NO in PAs. ARS and its derivatives might have the potential to be novel drugs for the treatment of PH.

18 May 2026 in Circulation Research
Verified
Journal Article
Closed access
JKJason H. Karnes
Jason H. Karnes
CBChanglei Bao
Changlei Bao
SLShuxin Liang
Shuxin Liang
TTTimothy Thayer
Timothy Thayer
JZJohn Zagorski
John Zagorski
ADAnkit A. Desai
Ankit A. Desai
BACKGROUND: Although pulmonary arterial hypertension (PAH) is a rare and fatal disease that is well-characterized, vasodilator-responsive PAH accounts for a minority of cases, with little mechanistic knowledge, but with dramatically improved survival. METHODS: By assembling national cohorts, we evaluated genetic influences on acute vasodilator drug response, a key determinant of the presence of vasodilator-responsive PAH. Differences between hemodynamics at rest and after a PAH-specific vasodilator were tested in a genome-wide association study. Validated loci were functionally tested in cell culture and in a hypoxic mouse model of pulmonary hypertension. RESULTS: Rs8057488 in the sorting nexin 29 ( SNX29 ) gene reached genome-wide significance in the discovery cohort ( P =4.00×10 −8 ) and was nominally replicated ( P =0.027). Consistent with its predicted function, SNX29 demonstrated an endosomal distribution in PA smooth muscle cells. Silencing SNX29 redistributed stromal interaction molecule proteins to the cell membrane and enhanced store-operated calcium entry. Over-expression of SNX29, in vivo, attenuated hypoxic vasoconstriction in isolated perfused murine lung models. CONCLUSIONS: The data cumulatively suggest SNX29 may contribute to vasodilation partly through reduced store-operated calcium entry and endosomal trafficking of store-operated calcium entry proteins, advancing our understanding of vasodilator-responsive PAH.

12 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JBJune Bai
June Bai
HSHanliang Sun
Hanliang Sun
CHChuangjia Huang
Chuangjia Huang
DBDan Bai
Dan Bai
JZJinsheng Zhu
Jinsheng Zhu
HTHaiyang Tang
Haiyang Tang
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized primarily by sustained pulmonary vasoconstriction, pulmonary vascular remodeling, and elevated pulmonary artery pressure. Recent emerging studies have indicated that mitochondria-endoplasmic reticulum (ER) membrane (MAM) is increasingly implicated in pathogenesis of pulmonary hypertension (PH). Dysfunction of mitochondria or ER can trigger a series of pathological processes, including disrupted intracellular Ca2+ homeostasis, oxidative stress, ER stress, and inflammation, which in turn drive dysfunction of pulmonary artery smooth muscle (PASMCs) and endothelial cells (PAECs). This review article aims to systematically evaluates the pathogenic mechanisms of the MAM in PH, covering the latest research advances in mitochondrial dynamic disorders, Ca2+ homeostasis, ER stress, oxidative stress, cellular metabolic reprogramming, and inflammatory responses. Special focus is placed on the structural and functional regulatory mechanisms of MAMs and their roles in pulmonary vascular functional and structural dysfunction. Furthermore, the current review also discusses the potential of new and efficacious therapeutic strategies targeting mitochondrial dysfunctions and ER stress for treatments of PH.

1 July 2026 in Hypertension
Verified
Journal Article
Closed access
JLJianmin Lu
Jianmin Lu
HLHuizhao Liao
Huizhao Liao
ZHZijie Huang
Zijie Huang
CBChanglei Bao
Changlei Bao
TSTingting Sun
Tingting Sun
CHCheng Hong
Cheng Hong
BACKGROUND: Perivascular inflammation induced by abnormal hemodynamic stress is increasingly recognized as a key driver of secondary microvasculopathy in chronic thromboembolic pulmonary hypertension. Although circulating CXCL10 (C-X-C motif chemokine ligand 10) is elevated in chronic thromboembolic pulmonary hypertension and correlates with pulmonary hemodynamics, its mechanistic contribution to vascular remodeling remains unclear. METHODS: Experiments were performed using pulmonary endarterectomy specimens from patients with chronic thromboembolic pulmonary hypertension and a left pulmonary artery ligation rat model. RESULTS: In pulmonary endarterectomy specimens, CXCL10 was predominantly localized to CD68+ mannose receptor C-type 1+ macrophages, whereas CXCR3 (C-X-C motif chemokine receptor 3) was broadly expressed in the vascular wall and enriched in distal nonoccluded pulmonary arteries with increased mannose receptor C-type 1+ macrophage accumulation. In left pulmonary artery ligation rats, pulmonary hypertension and vascular remodeling were accompanied by perivascular accumulation of CXCL10+CXCR3+ mannose receptor C-type 1+ macrophages, increased plasma CXCL10, and upregulation of CXCL10 and CXCR3 in the right lung. CXCR3 expression was also increased in pulmonary arterial smooth muscle cells (PASMCs), and CXCL10 directly promoted proliferation of left pulmonary artery ligation-derived PASMCs in a CXCR3-dependent manner. In parallel, CXCL10 drove macrophages toward a proinflammatory, pro-proliferative secretory phenotype, and conditioned medium from macrophages enhanced PASMC proliferation. Pharmacological CXCR3 inhibition with AMG487 attenuated pulmonary hypertension, vascular remodeling, PASMC proliferation, and perivascular macrophage accumulation in both preventive and therapeutic settings. Similarly, cell type-specific CXCR3 knockdown in smooth muscle cells or macrophages ameliorated left pulmonary artery ligation-induced pulmonary hypertension, vascular remodeling, and associated perivascular inflammation. CONCLUSIONS: The CXCL10/CXCR3 axis links hemodynamic stress to pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension by coordinating PASMC hyperproliferation and macrophage-driven inflammation, and may represent a therapeutic target.

1 July 2026 in Hypertension
Verified
Journal Article
Closed access
RHRuihua Hu
Ruihua Hu
JBJie Bai
Jie Bai
YPYan Pan
Yan Pan
DLDingyuan Liu
Dingyuan Liu
CLCaiyu Li
Caiyu Li
HYHan Ying
Han Ying
BACKGROUND: A hallmark of pulmonary hypertension (PH) is the progressive increase in pulmonary arterial resistance caused by impaired pulmonary artery (PA) relaxation and vascular remodeling. Salusin-α, a cardiovascular-active peptide, has been implicated in several cardiovascular diseases; however, its role in PH remains undefined. METHODS: PAs were isolated from rats for isometric tension recording to assess relaxation. PA remodeling was quantified using histological morphometric analysis. Right ventricular pressure and hypertrophy were measured to evaluate PH severity. RESULTS: Salusin-α levels were significantly decreased in both plasma and PAs from PH rats compared with controls. Both acute and chronic salusin-α administration improved endothelium-dependent and -independent PA relaxation, increased endothelial nitric oxide synthase activity and nitric oxide levels in PA endothelial cells, enhanced Nrf2 (nuclear factor erythroid 2-related factor 2) and superoxide dismutase expression and activity in PA smooth muscle cells, and decreased NAD(P)H oxidase expression, activity, and reactive oxygen species levels. Salusin-α also inhibited PA smooth muscle cell proliferation and migration, attenuated pulmonary vascular remodeling, and decreased right ventricular pressure, hypertrophy, and mortality in PH rats. Neutralizing endogenous salusin-α exerted opposite effects. Pharmacological inhibition demonstrated that endothelial nitric oxide synthase and superoxide dismutase contributed to the protective actions of salusin-α, whereas NAD(P)H oxidase inhibition or reactive oxygen species scavenging prevented the effects of salusin-α neutralization. CONCLUSIONS: Salusin-α improves endothelium-dependent vasodilation via endothelial nitric oxide synthase mediated nitric oxide release in PA endothelial cells, and promotes endothelium-independent vasodilation while attenuating pulmonary vascular remodeling via inhibition of NAD(P)H oxidase-reactive oxygen species signaling and activation of the Nrf2/superoxide dismutase signaling. Restoring reduced salusin-α may present a novel therapeutic strategy for PH treatment.